Cognition, schizophrenia and the effect of antipsychotics;Cognition, schizophrénie et effet des antipsychotiques: Le point de vue d'un laboratoire de recherche clinique

Encephale

Volumn 32, Issue 3, 2006, Pages 341-350

  Stip, E ^a  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Antipsychotics; Clozapine; Cognition; Ecological validity of testing; Executive function; Olanzapine; Procedural learning; Risperidone; Schizophrenia; SSTICS; Subjective complaints

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ATTENTION; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COOKING; CORPUS STRIATUM; CORRELATION ANALYSIS; DRUG EFFECT; HUMAN; LEARNING; LEARNING DISORDER; MEDICAL RESEARCH; MENTAL TASK; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PROBLEM SOLVING; QUALITY OF LIFE; RATING SCALE; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SENSORIMOTOR FUNCTION; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TASK PERFORMANCE;

EID: 33745389690     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0013-7006(06)76162-0     Document Type: Article

References (44)

1. BADDELEY A. Working Memory. Oxford : Clarendon Press, 1986.
2. BILDER RM, GOLDMAN RS, VOLAVKA J et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002 ; 159 : 1018-28.
3. BYMASTER FP, RASMUSSEN K, CALLIGARO DO et al. In vitro and in vivo biochemistry of olanzapine : a novel, atypical antipsychotic drug. J Clin Psychiatry 1997 ; 58 (Suppl 10) : 28-36.
4. CHAKOS MH, LIEBERMAN JA, ALVIR J et al. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 1995 ; 345 : 456-7.
5. FAHIM C, MANCINI-MARIE A, MENSOUR B et al. Neural substrates of sadness in schizophrenia : an fMRI study International. J Psychophysiol 2002 (45) : 124-5.
6. GALHOFER B, LIS S, MEYER-LINDENBERG A et al. Cognitive dysfunction in schizophrenia : a new set of tools for the assessment of cognition and drug effects. Acta Psychiatr Scand 1999 ; 395 : 118-28.
7. GEDDES J, FREEMANTLE N, HARRISON P et al. Atypical antipsychotics in the treatment of schizophrenia : systematic overview and meta-regression analysis. Br Med J 2000 ; 321 : 1371-6.
8. GOLDBERG TE, TORREY EF, GOLD JM et al. Learning and memory in monozygotic twins discordant for schizophrenia. Psychol Med 1993 ; 23 : 71-85.
9. GOLDBERG TE, WEINBERGER DR. Thought disorder, working memory and attention : interrelationships and the effects of neuroleptic medications. Int Clin Psychopharmacol 1995 ; 10 (Suppl 3) : 99-104.
10. GREEN MF, KERN RS, BRAFF DL et al. Neurocognitive deficits and functional outcome in schizophrenia : are we measuring the «right stuff» ? Schizophr Bull 2000 ; 26 : 119-36.
11. GREEN MF, MARDER SR, GLYNN SM et al. The neurocognitive effects of low-dose halopéridol : a two-year comparison with risperidone. Biol Psychiatry 2002 ; 51 : 972-8.
12. GREEN MF, NUECHTERLEIN KH, GOLD JM et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia : the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004 ; 56 : 301-7.
13. HARVEY PD, GREEN MF, McGURK SR et al. Changes in cognitive functioning with risperidone and olanzapine treatment : a large-scale, double-blind, randomized study. Psychopharmacology 2003 ; 169 : 404-11.
14. HOGARTY GE, FLESHER S, ULRICH R et al. Cognitive enhancement therapy for schizophrenia : effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry 2004 ; 61 (9) : 866-76.
15. KASPER S, RESINGER E. Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 2003 ; 28 (Suppl 1) : 27-38.
16. KEEFE RS, SEIDMAN LJ, CHRISTENSEN BK et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis : a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004 ; 161 : 985-95.
17. KEEFE RS, SILVA SG, PERKINS DO et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia : a review and meta-analysis. Schizophr Bull 1999 ; 25 : 201-22.
18. th International Congress on schizophrenia. Schizophr Res 2001 ; 49 (Suppl. 1-2) : 263.
19. LIDDLE PF. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br J Psychiatry 1987 ; 151 : 145-51.
20. LIDDLE PF, FRISTON KJ, FRITH CD et al. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992 ; 160 : 179-86.
21. LUSSIER I, STIP E. Memory and attention deficits in drug naive patients with schizophrenia. Schizophr Res 2001 ; 48 : 45-55.
22. MANSCHRECK TC, REDMOND DA, CANDELA SF et al. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. J Neuropsychiatr Clin Neurosci 1999 ; 11 : 481-9.
23. MARDER SR, FENTON W. Measurement and treatment research to improve cognition in schizophrenia : NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004 ; 72 : 5-9.
24. McGURK SR. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 1999 ; 60 (Suppl 12) : 24-9.
25. MELTZER HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999 ; 2 : 106S-115S.
26. MENDREK A, LAURENS KR, KIEHL KA et al. Changes in distributed neural circuitry function in patients with first-episode schizophrenia. Br J Psychiatry 2004 ; 185 : 205-14.
27. PROUTEAU A, VERDOUX H, BRIAND C et al. The crucial role of sustained attention in community functioning in outpatients with schizophrenia. Psychiatry Res 2004 ; 129 : 171-7.
28. PURDON SE. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res 1999 ; 35 : S51-60.
29. PURDON SE, JONES BD, STIP E et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000 ; 57 : 249-58.
30. PURDON SE, WOODWARD N, LINDBORG SR et al. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology (Berl) 2003 ; 169 : 390-7.
31. RIVARD S, CLOUTIER C, STIP E et al. Assessment of daily activities in young adults with schizophrenia. Schizophr Res 2004 ; 70 (1) : 102-3.
32. SCHOTTE A, JANSSEN PF, GOMMEREN W et al. Risperidone compared with new and reference antipsychotic drugs : in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996 ; 124 : 57-73.
33. SEMKOVSKA M, BÉDARD MA, GODBOUT L et al. Assessment of executive dysfunction during activities of daily living in schizophrenia. Schizophr Res 2004 ; 69 (2-3) : 289-300.
34. SEMKOVSKA M, STIP E, GODBOUT L et al. Behavioral disorganization in schizophrenia during a daily activity : the kitchen behavioral scoring scale. Brain Cogn 2002 ; 48 : 546-53.
35. SHARMA T. Impact on cognition of the use of antipsychotics. Curr Med Res Opin 2002 ; 18 (Suppl 3) : S13-7.
36. SHARMA T, HUGHES C, SONI W et al. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology 2003 ; 169 (3-4) : 398-403.
37. SQUIRE LR, ZOLA SM. Structure and function of declarative and nondeclarative memory systems. Proc Natl Acad Sci USA 1996 ; 93 : 13515-22.
38. STIP E. La schizophrénie. In : Botez ML, ed. Neuropsychologie clinique et neurologie de comportement. Paris : Masson, 2005.
39. STIP E, CARON J, RENAUD S et al. Exploring cognitive complaints in schizophrenia : the subjective scale to investigate cognition in schizophrenia. Compr Psychiatry 2003 ; 44 : 331-40.
40. STIP E, FAHIM C, MENSOUR B et al. Does blunted affect in schizophrenia improve with quetiapine ? A functional magnetic resonance imaging study. Int J Neuropsychopharmacol 2002 ; 5 (Suppl 1) : S72-S73.
41. STIP E, LUSSIER I. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 1996 ; 41, 8 (Suppl 2) : S35-40.
42. STIP E, REMINGTON GJ, DURSUN SM et al. Canadian Switch Study Group. A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. J Clin Psychopharmacol 2003 ; 23 : 400-4.
43. STIP E, RIALLE V. Environmental cognitive remediation in schizophrenia : ethical implications of «Smart Home» technology. Can J Psychiatry 2004 ; 15 (5) : 281-91.
44. VELLIGAN DI, NEWCOMER J, PULTZ J et al. Does cognitive function improve with quetiapine in comparison to halopéridol ? Schizophr Res 2002 ; 53 : 239-48.